Literature DB >> 3446307

Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia.

D A Johnson1, J M Ludlow, K Street, R D Taylor.   

Abstract

A double-blind controlled trial of 50% dose reduction in maintenance treatment in stable out-patients with low BPRS scores and good social function shows a significantly higher relapse rate in the low-dose group at 12 months (P less than 0.05). After an interval of 24-36 months from dose reduction, 56-76% had experienced a relapse and 76-79% had resumed their former dosage. No clear advantage was shown for the lower dose in either a reduction of side-effects or improved social function, but a reduced prevalence or lower rate of symptom emergence for tardive dyskinesia was suggested.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3446307     DOI: 10.1192/bjp.151.5.634

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  13 in total

1.  A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.

Authors:  Adil E Shamoo; Dianne N Irving; Patricia Langenberg
Journal:  Sci Eng Ethics       Date:  1997-10       Impact factor: 3.525

Review 2.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

4.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

Review 5.  Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.

Authors:  N R Schooler; S J Keith; J B Severe; S M Matthews
Journal:  Psychiatr Q       Date:  1995

6.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 7.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

8.  Reducing the dose of depot neuroleptics in stable schizophrenia.

Authors:  R Dale; M Longdon; M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

Review 9.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

Review 10.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.